Lin28 Regulates Cancer Cell Stemness for Tumour Progression
department or school: Land and Food Systems, Faculty of
department or school: Medicine, Faculty of
department or school: Science, Faculty of
department or school: Non UBC
department or school: Microbiology and Immunology, Department of
department or school: Urologic Sciences, Department of
data provider: DSpace
identifier citation: Cancers 14 (19): 4640 (2022)
contributor: Vancouver Prostate Centre
creator: Lin, Zhuohui
creator: Radaeva, Mariia
creator: Cherkasov, Artem
creator: Dong, Xuesen
issued: 2024-11-01T17:25:06Z
issued: 2022-09-24
description: Tumours develop therapy resistance through complex mechanisms, one of which is that cancer stem cell (CSC) populations within the tumours present self-renewable capability and phenotypical plasticity to endure therapy-induced stress conditions and allow tumour progression to the therapy-resistant state. Developing therapeutic strategies to cope with CSCs requires a thorough understanding of the critical drivers and molecular mechanisms underlying the aforementioned processes. One such hub regulator of stemness is Lin28, an RNA-binding protein. Lin28 blocks the synthesis of let-7, a tumour-suppressor microRNA, and acts as a global regulator of cell differentiation and proliferation. Lin28also targets messenger RNAs and regulates protein translation. In this review, we explain the role of the Lin28/let-7 axis in establishing stemness, epithelial-to-mesenchymal transition, and glucose metabolism reprogramming. We also highlight the role of Lin28 in therapy-resistant prostate cancer progression and discuss the emergence of Lin28-targeted therapeutics and screening methods.
aggregated CHO: https://circle.library.ubc.ca/rest/handle/2429/89590
note: Citation: Lin, Z.; Radaeva, M.;Cherkasov, A.; Dong, X. Lin28Regulates Cancer Cell Stemness forTumour Progression. Cancers 2022, 14,4640. https://doi.org/10.3390/cancers14194640Academic Editor: Kavita ShahReceived: 19 August 2022Accepted: 22 September 2022Published: 24 September 2022Publisher’s Note: MDPI stays neutralwith regard to jurisdictional claims inpublished maps and institutional affil-iations.Copyright: © 2022 by the authors.Licensee MDPI, Basel, Switzerland.This article is an open access articledistributed under the terms andconditions of the Creative CommonsAttribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).cancersReviewLin28 Regulates Cancer Cell Stemness for Tumour ProgressionZhuohui Lin 1,2,† , Mariia Radaeva 3,*,† , Artem Cherkasov 3 and Xuesen Dong 31 Department of Microbiology and Immunology, University of British Columbia,Vancouver, BC V6T 1Z4, Canada2 Faculty of Food and Land Systems, University of British Columbia, Vancouver, BC V6T 1Z4, Canada3 The Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia,Vancouver, BC V6H 3Z6, Canada* Correspondence: mradaeva@prostatecentre.com† These authors contributed equally to this work.Simple Summary: Cancer stem cells (CSCs) are a small population of tumour cells bearing stemnesscharacteristics. They have been deemed as a root of cancer development and a promising drug targetfor anticancer therapy. Herein, we discuss the roles of an RNA-binding protein, Lin28, in regulatingcancer cell stemness to drive tumour progression. Lin28 acts on various types of RNAs in cancercells and regulates these RNA functions to control the expression of oncogenes. In these ways, Lin28promotes cancer cell survival, growth, and invasion. We also discuss recent efforts in developingLin28 inhibitors targeting CSCs in tumours.Abstract: Tumours develop therapy resistance through complex mechanisms, one of which is thatcancer stem cell (CSC) populations within the tumours pr…
has type: Article
is shown at: 10.14288/1.0447193
language: eng
peer review status: Reviewed
provider: Vancouver : University of British Columbia Library
publisher: Multidisciplinary Digital Publishing Institute
publisher DOI: 10.3390/cancers14194640
rights: CC BY 4.0
rights URI: https://creativecommons.org/licenses/by/4.0/
scholar level: Faculty
scholar level: Researcher
subject: Lin28
subject: let-7
subject: metastasis
subject: metabolism
subject: epithelial-to-mesenchymal transition
subject: prostate cancer
subject: cancer stem cell
subject: Lin28 inhibitors
type: Text
identifier URI: http://hdl.handle.net/2429/89590